Cannabis Production in the European Union - Spectrum Denmark Granted Production Licence

Odense, Denmark, and Smiths Falls, Ontario (ots/PRNewswire) -

Further to a December 5th press release announcing plans to
establish a 40,000 m2 facility in the Danish city of Odense, Spectrum
Cannabis Denmark has been issued a cannabis production licence by
Laegemiddelstyrelsen, Denmark's Medicines Agency. Danish Health
Minister, Ellen Trane Nørbye, announced the news today at a press
conference. Spectrum Cannabis Denmark is a partnership between Danish
Cannabis, one of Europe's largest hemp producers, and Canopy Growth
Corporation ("Canopy Growth" or the "Company") (TSX: WEED).

To the Company's knowledge, this is the first federal production
licence issued to a Canadian cannabis producer anywhere in the
European Union, a major milestone in an emerging market. With the
announcement, Denmark has joined the Netherlands as the only two
European countries with federally permitted medical cannabis
production.

Speaking to local media, Minister Nørbye commented, "Medical
cannabis has enormous potential and my role as Minister of Health is
to help secure that the new medical cannabis law becomes a success
for patients and for Denmark."

Cannabis produced at the Odense facility is forecasted to exceed
the needs of the Danish market and will be exported to other
federally legal jurisdictions in the European Union.

"Entering Denmark was a strategic choice for us because we sensed
the country would move fast to establish federal production
capabilities. Using our expertise and in collaboration with excellent
local partners, Canopy is now set to become the first ACMPR
participant to also produce cannabis products in the European Union,"
said Bruce Linton, Chairman and CEO, Canopy Growth. "In 2014 we began
with a small Canadian patient group and grew it rapidly by offering
high-quality products and actively engaging with the medical
community. We intend to repeat this model of success on the other
side of the Atlantic and solidify our position as the global leaders
in the cannabis industry."

Canopy Growth has stabilized an industry-leading selection of
cannabis genetics in its Canadian facilities and will ship a variety
of Spectrum Cannabis clones to Odense to begin growth cycles as soon
as spring 2018 when the greenhouse retrofit is targeted to be
complete.

The licence is being issued without conditions, meaning that
Spectrum Cannabis Denmark will not be limited to a production cap or
limited to the product formats it can produce. High quality oils and
dried cannabis flowers will be produced in Odense and sold under the
Spectrum Cannabis brand using the proprietary Spectrum colour-coded
strain classification system.

As in Canada, Canopy Growth will use its experience to engage the
physician community in Denmark to ensure that physicians are able to
access fact-based information pertaining to dosing, and prescribing
to appropriate patients.

The licence announced today is valid through 2021.

Here's to Future Growth.

About Canopy Growth Corporation

Canopy Growth is a world-leading diversified cannabis and hemp
company, offering distinct brands and curated cannabis varieties in
dried, oil and Softgel capsule forms. From product and process
innovation to market execution, Canopy Growth is driven by a passion
for leadership and a commitment to building a world-class cannabis
company one product, site and country at a time.

Canopy Growth has established partnerships with leading sector
names including cannabis icon Snoop Dogg, breeding legends DNA
Genetics and Green House seeds, and Fortune 500 alcohol leader
Constellation Brands, to name but a few. Canopy Growth operates seven
cannabis production sites with over 665,000 square feet of production
capacity, including over 500,000 square feet of GMP-certified
production space. The Company has operations in seven countries
across four continents. The Company is proudly dedicated to educating
healthcare practitioners, conducting robust clinical research, and
furthering the public's understanding of cannabis, and through its
partly owned subsidiary, Canopy Health Innovations, has devoted
millions of dollars toward cutting edge, commercializable research
and IP development. Through partly owned subsidiary Canopy Rivers
Corporation, the Company is providing resources and investment to new
market entrants and building a portfolio of stable investments in the
sector. From our historic public listing to our continued
international expansion, pride in advancing shareholder value through
leadership is engrained in all we do at Canopy Growth. For more
information visit http://www.canopygrowth.com

Notice Regarding Forward Looking Statements

This news release contains forward-looking statements. Often, but
not always, forward-looking statements can be identified by the use
of words such as "plans", "expects" or "does not expect", "is
expected", "estimates", "intends", "anticipates" or "does not
anticipate", or "believes", or variations of such words and phrases
or state that certain actions, events or results "may", "could",
"would", "might" or "will" be taken, occur or be achieved.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of Canopy Growth Corporation, its
subsidiaries, or its affiliates to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Examples of such statements include
future operational and production capacity, the impact of enhanced
infrastructure and production capabilities, and forecasted available
product selection. The forward-looking statements included in this
news release are made as of the date of this news release and Canopy
Growth Corporation does not undertake an obligation to publicly
update such forward-looking statements to reflect new information,
subsequent events or otherwise unless required by applicable
securities legislation.

Neither the TSX Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Exchange) accepts
responsibility for the adequacy or accuracy of this release.

Jordan Sinclair, Director of Communications, Jordan@tweed.com,
613-769-4196; Investor Relations, Tyler Burns,
Tyler.burns@canopygrowth.com , +1-855-558-9333 ex 122; Director:
Bruce Linton, tmx@tweed.com

ots Originaltext: Canopy Growth Corporation
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: Canopy Growth Corporation, übermittelt durch news aktuell